Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structura... by Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Shingo Wada, Wen Shi Lee, Dilinuer Ainiwaer, Koki Idehara, Sona-Sanae Aoyagi, Seok-Won Kim, Todd Taylor

“…Included patients had a confirmed diagnosis of DLBCL, received allogeneic SCT (allo-SCT) or autologous SCT (ASCT) after the first DLBCL diagnosis, and received high-dose chemotherapy during the 6-month look-back period. The results confirmed that no patients had allo-SCT, hence only ASCT was included in the analysis. …”
Get full text

Adverse health effects after breast cancer up to 14 years after diagnosis by Marianne J. Heins, Kelly M. de Ligt, Janneke Verloop, Sabine Siesling, Joke C. Korevaar, Annette Berendsen, Daan Brandenbarg, Anneriet Dassen, Agnes Jager, Jacqueline Hugtenburg, Gerda van der Weele

“…Osteoporosis and chest symptoms were associated with hormone therapy; osteoporosis and skin infections with chemotherapy and lymphedema and skin infections with axillary dissection. …”
Get full text

Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer by Pankaj Ahluwalia, Ashis K. Mondal, Ashutosh Vashisht, Harmanpreet Singh, Ahmet Alptekin, Kalyani Ballur, Nivin Omar, Meenakshi Ahluwalia, Kimya Jones, Amanda Barrett, Vamsi Kota, Ravindra Kolhe

“…Despite advances in diagnosis and treatment, including surgery, chemotherapy, and immunotherapy, accurate clinical markers are still lacking. …”
Get full text

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response by Jing Wang, Jin Wang, Yi-Na Wang, Yuan-Yuan Wang, Wen-Juan Bai, Nai-Jun Miao

“…As a microtubule-targetting drug, vinblastine (VBL) has been used in chemotherapy. However, no study to date has explored the effect of VBL on TAM shape changes and its role in tumor immune response.Method We used fluorescent staining of the cytoskeleton and quantitative analysis to reveal the morphological differences between M0, M1, M2, TAM and VBL-treated TAM. …”
Get full text

ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation by Jiaxing Zhang, Jiaxing Zhang, Gang Wang, Jie Liu, Futian Tang, Song Wang, Yumin Li, Yumin Li

“…It could also predict immunotherapy efficacy and chemotherapy sensitivity. In GC, high ITGA4 expression was related to poor prognosis, promoted tumor proliferation and migration, and enhanced immune cell infiltration. …”
Get full text

Construction and evaluation of a prognostic model for cervical cancer based on dynamic hematological and clinical features by Huangrong Ma, Lingyu Ma, Li Yang, Miaoying Cai, Yifu Wang, Yue Li, Chunyu Liang, Zhiyuan Xu

“…The final multivariate analysis incorporating all clinical factors, hematological variables, and inflammatory markers identified the following prognostic factors: FIGO2018 staging, rate of tumor shrinkage before brachytherapy, pre-treatment albumin levels, treatment times, minimum neutrophils during treatment, concurrent chemotherapy cycles, and lymphopenia grade. Calibration plots showed agreement between the OS predicted by the nomograms and actual OS. …”
Get full text

Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4 by Rongyu Shi, Ning Zhang, Han Li, Hu Zhong, Chengcheng Zhong, Wei Du, Xi Yang

“…Methods In total, 60 newly diagnosed PC patients only with GEM-based chemotherapy were recruited. Normal fibroblasts (NFs) and CAFs were isolated using fresh normal and resistant PC tissues. …”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

“…Results: All patients were diagnosed with a metastatic adenocarcinoma, had previously progressed on at least one line of chemotherapy and had been previously treated with trastuzumab-deruxtecan (two had to stop treatment because of pneumonitis). …”
Get full text

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting by Yilan Xu, Danyang Li, Na Wang, Bei Ge, Chen Meng, Min Zhao, Zihan Lin, Min Li, Yigang Yuan, Yue Cai, Liuzhi Shi, Shenmeng Gao, Haige Ye

“…Abstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive. …”
Get full text

Early tolerance and late persistence as alternative drug responses in cancer by Simona Punzi, Davide Cittaro, Guido Gatti, Gemma Crupi, Oronza A. Botrugno, Antonino Alex Cartalemi, Alon Gutfreund, Caterina Oneto, Valentina Giansanti, Chiara Battistini, Giovanni Santacatterina, Lucrezia Patruno, Ilaria Villanti, Martina Palumbo, Daniel J. Laverty, Francesca Giannese, Alex Graudenzi, Giulio Caravagna, Marco Antoniotti, Zachary Nagel, Ugo Cavallaro, Luisa Lanfrancone, Timothy A. Yap, Giulio Draetta, Nathalie Balaban, Giovanni Tonon

“…Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. …”
Get full text

Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis by Megan Chua Wern Ee, Ashley Lee Shi Hui, Wong Hung Chew, Emmeline Elaine Cua-Delos Santos, Sean Li Siwei, Sng Ming Xian, Qin Xiang Ng, Serene Goh Si Ning

“…Advances in neoadjuvant chemotherapy (NACT), breast-conserving surgery (BCS), and radiation have transformed treatment into a multimodal approach. …”
Get full text

Race as a prognostic factor of breast mucinous carcinoma by Dingyuan Wang, Yang Wang, Songlin Gao, Rongshou Zheng, Guijian Wu, Jianping Wang, Can Lu, Kena Bu, Chun Zhang, Wanqing Chen, Bailin Zhang

“…Specifically, non-Chinese American patients had a worse OS compared to Chinese patients (adjusted HR = 2.59, 95% CI: 1.15–5.83, P = 0.022). Chemotherapy significantly improved OS only in black BMC patients (adjusted HR = 0.52, 95% CI: 0.27–0.98, p = 0.045), but not in other racial/ethnic groups. …”
Get full text

The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy by M.C. Van Maaren, T.A. Hueting, D.J.P. van Uden, M. van Hezewijk, L. de Munck, M.A.M. Mureau, P.A. Seegers, Q.J.M. Voorham, M.K. Schmidt, G.S. Sonke, C.G.M. Groothuis-Oudshoorn, S. Siesling

“…Age, mode of detection, histology, sublocalisation, grade, pT, pN, hormonal receptor status ± endocrine treatment, HER2 status ± targeted treatment, surgery ± immediate reconstruction ± radiation therapy, and chemotherapy were significant predictors for LRR and/or CBC in non-NST patients. …”
Get full text

Treatment of autonomous intestinal neuropathy in critical care by prucalopride and multistrain probiotic by A. L. Kovaleva, A. I. Ulyanin, O. Yu. Kiselyova, Ye. A. Poluektova, O. S. Shifrin, A. S. Tertychny, V. T. Ivashkin

“…According to the past history in 2014 patient was diagnosed to have adenocarcinoma of the right breast gland with subsequent right-sided radical mastectomy followed by radiation therapy and chemotherapy. In May 2017 patient developed boring pain in the right lumbar area, frequent small-volume urination, febrile fever and progressive general weakness. …”
Get full text

Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated pati... by Kai-Lin Yang, Mau-Shin Chi, Chung-Yu Hao, Hui-Ling Ko, Yi-Ying Huang, Ren-Hong Wu, Hung-Chih Lai, Ying-Chu Lin, Sheng-Po Hao, Kwan-Hwa Chi

“…Weekly hyperthermia for 6 sessions started after RT initiation; each session lasted for 40 min, beginning within 2 h after RT and maintaining a maximum temperature of 42 ± 0.5 °C. Concurrent chemotherapy included weekly cisplatin 20 mg/m2 and docetaxel 10–12 mg/m2 for 6 weeks. …”
Get full text

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

“…These findings underscore the need for updated clinical guidelines that address evolving pathogen profiles and the growing challenge of MDR infections.Summary: Infection-related complications remain a leading cause of mortality in HM patients, often limiting the implementation of chemotherapy. Early and appropriate empirical therapy significantly improves outcomes in FN, reducing hospital stays and healthcare costs. …”
Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

“…Accumulating evidence suggests rationales for continuing immunotherapy beyond progression, synergistic effects between immune checkpoint inhibitors and angiogenesis inhibitors, and a preferable combination of steroid-free chemotherapy with immunotherapy. These rationales imply that nanoparticle albumin-bound (nab)-paclitaxel plus ramucirumab in combination with nivolumab (anti-PD-1 antibody) may enhance anti-tumor effects as second-line treatment. …”
Get full text

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives by Héverton Mendes Araújo, Gabriel Acácio de Moura, Yasmim Mendes Rocha, Cristian Vicson Pinheiro Gomes, Valentina Nascimento e Melo de Oliveira, Ronaldo Nascimento de Oliveira, Larissa Deadame de Figueiredo Nicolete, Emanuel Paula Magalhães, Ramon R.P.P.B. de Menezes, Roberto Nicolete

“…However, for more advanced cases with a high recurrence rate, the preferred approach is to combine chemotherapy with immunotherapy treatments. Tumor-associated macrophages (TAMs) are the most abundant leukocytes in solid tumors. …”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. …”
Get full text

Shaoyao Gancao decoction alleviates paclitaxel-induced cognitive impairment by activating PTEN/PI3K/AKT pathway to inhibit NETs formation by Xu Ying, Su Yue, Hu Yuwen, Li Xiang, Zhou Ziyan, Yuan Ningning, Ji Xiaowei, Jiang Ruoyu, Wang Wenzhu, Zhang Yafeng, Zhai Guojie, Cheng Xiaolan

“…Purpose: Paclitaxel-induced cognitive impairment (PICI) is a frequent and severe adverse reaction of chemotherapy. Increased neuroinflammation related to neutrophil extracellular traps (NETs) may play a key role in PICI. …”
Get full text